Search company, investor...
Biofourmis company logo


Founded Year



Series D - II | Alive

Total Raised


Last Raised

$20M | 4 mos ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+20 points in the past 30 days

About Biofourmis

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. It serves clients operating in the healthcare sector. The company was founded in 2015 and is based in Boston, Massachusetts.

Headquarters Location

33 Arch Street Floor 17

Boston, Massachusetts, 02110,

United States

(617) 334-5441

ESPs containing Biofourmis

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Healthcare Providers Tech

As remote monitoring and home health has become more common, it’s become vital for healthcare organizations to be able to integrate, monitor, and analyze the data from these devices.

Biofourmis named as Leader among 15 other companies, including Huma, Withings, and Cadence.

Compete with Biofourmis?

Ensure that your company and products are accurately represented on our platform.

Biofourmis's Products & Differentiators

    Biovitals RPM

    Remote patient monitoring platform

Expert Collections containing Biofourmis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biofourmis is included in 15 Expert Collections, including Digital Health.


Digital Health

22,964 items

Startups recreating how healthcare is delivered


Unicorns- Billion Dollar Startups

1,201 items


Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry


Value-Based Care & Population Health

1,060 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.


Medical Devices

12,285 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Latest Biofourmis News

“Even with a likely global recession upon us, we are bullish on the opportunities to invest”

Nov 24, 2022

(Photo: Bartzi Goldblat) Name of fund/funds: Intel CapitalTotal sum of fund: Investing $350-500M annuallyManaging Partners: Dave Flanagan, Andy Fligel, Anthony Lin, Mark Rostick, Trina Van Pelt, Nick WashburnNotable/select portfolio companies: MinIO, Anyscale, DataRobot, Immuta, Lightbits, Neuroblade, Motivo, SambaNova, 3D Glass Solutions, Astera Labs, Overwolf, BoomTV, Aledia, BlueStacks, Syntiant, Orcam, Joby, Beep, Fabric8Labs, Exo Imaging Bar-Kat joined CTech to discuss some of the trends in more detail. If 2020 was the year of the pandemic, and 2021 was the year of records, how would you define 2022 in the VC sector? I think of 2022 as the year of early-stage investments. We’ve seen late-stage investment activity decline throughout this year, causing some to think the overall investing landscape was shifting, but not all investing activity had the same fate. Amid ongoing public market turbulence, VCs shifted their focus to early-stage (Seed and Series A) companies. I love getting in early with a company that’s led by a strong, intelligent team and is solving a real problem in a significant market, and supporting them through their growth. Who are the big winners of 2022 and why? Companies that are truly solving a major pain point for their customers, and doing so better than their competitors, were the big winners of 2022. It’s no longer enough to just have a well-made product. Companies that cut through the noise, while adhering to efficient go-to-market methods, are those that differentiate themselves from their competitors and deliver real value to their customers. Industry-speaking, in Israel, AI and Cybersecurity were winners of 2022. In Q1 2022 alone, cybersecurity startups raised $1.7 billion and AI startups raised $942 million. Who are the big losers of 2022 and why? Companies that catered to short-term trends and lacked long-term market potential were the losers of 2022. Hopping on the hype cycle of the new, shiny technology isn’t always sustainable and the success often doesn’t materialize as well as people think. That, coupled with high burn rates used to fuel attempts at rapid growth at the expense of efficiency, led to many unhealthy companies. What do you expect in the VC sector in 2023? There’s uncertainty in the market - and in the world in general; we’re all feeling it. But Intel Capital has invested through multiple major economic downturns and we’ve seen some of the most successful companies come out of recessions (Microsoft, Slack, Uber). So generally we’re optimistic, but also realistic in deploying capital against real market traction and we advise our portfolio to do the same. Throughout our current downturn, Israel has proved to have a thriving startup ecosystem, raising $506 per capita in 2022 amid funding constraints. I’m feeling relatively confident about Israeli VC in 2023. What global processes will affect (positively and negatively) the Israeli market? The global processes of other countries will have an impact on our market, just like they will globally. But, despite all of this, the Israeli market is poised to see economic growth of 5% in 2022 . Even with a likely global recession upon us, we are bullish on the opportunities to invest in meaningful technological and market innovation. How should different companies prepare for the coming year? Preparation is definitely key, here’s what I’m advising startups: Larger companies should think strategically about where they can cut costs, should it be additional tools, outsourcing, or even headcount. And should be very thoughtful and analytical in their choices. Medium-sized companies should streamline costs where they can, and, while it might seem counterintuitive, strategically invest in R&D to help create a strong foundation for a weakening economic landscape. Early-stage companies should forecast cash flow and focus on reserves, take a detailed look at the business and identify the most profitable offering – fine-tune it, focus on it and deliver. What will be of the dozens of unicorns born last year? Valuations ebb and flow, and with the stable of unicorns in the last year, some may end up losing their status. But, I wouldn’t view that as the end of the world or a detriment to the company. It’s the end game that counts. I have confidence that the unicorns as well as all startups with long-term market potential will continue to grow in 2023 and beyond. It’s all about long-term market potential. What sectors will experience an acceleration in VC investment and which will suffer a slowdown - and why? We’ve seen high-tech become increasingly prominent in the field of HR-Tech from recruiting to managing employees, and I think we’ll continue to see HR-Tech continue to advance and evolve. Given recent events, we’d expect to see a more cautious and diligent approach in the crypto sector. HR: Do the layoffs, those that have already happened and those that are coming, help to fix in any way the distress experienced by companies over the past 2-3 years? Layoffs - especially of high-tech employees - have been flooding our headlines over the past few weeks. It’s a natural part of the downcycle where companies will cut back from the overinvestment of the go-go years. Top-tier talent will always be in demand though, and we’d expect the market to remain competitive when it comes to attracting and retaining the best. Alkymi, Biofourmis, Inworld - Intel Capital’s notable portfolio companies AlkymiCloud: Alkymi is empowering businesses to unlock their data and supercharge their workflows. Founders: Harald Collet and Adam KleczewskiFounding year: 2019Number of employees: 53 Explanation behind investment: Intel Capital focuses greatly on companies that are making advancements in the Cloud BiofourmisFrontier: Biofourmis is a global technology-enabled care delivery platform company that enables the right care to be delivered to the right patient at the right time and place Founders: Kuldeep Singh Rajput and Mark NiuFounding year: 2016Number of employees: 550 Explanation behind investment: Important direction for the healthcare industry, revolutionizing patient care InworldCloud: Inworld provides a creative suite for building virtual characters, with a focus on gaming, metaverse, and brand experiences Founders: Ilya Gelfenbeyn, Michael Ermolenko and Kylan GibbsFounding year: 2021Number of employees: 46 Explanation behind investment: Developments in AI and communication TAGS

Biofourmis Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biofourmis Rank

Biofourmis Frequently Asked Questions (FAQ)

  • When was Biofourmis founded?

    Biofourmis was founded in 2015.

  • Where is Biofourmis's headquarters?

    Biofourmis's headquarters is located at 33 Arch Street, Boston.

  • What is Biofourmis's latest funding round?

    Biofourmis's latest funding round is Series D - II.

  • How much did Biofourmis raise?

    Biofourmis raised a total of $461.85M.

  • Who are the investors of Biofourmis?

    Investors of Biofourmis include Intel Capital, General Atlantic, CVS Health, OpenSpace Ventures, MassMutual Ventures and 12 more.

  • Who are Biofourmis's competitors?

    Competitors of Biofourmis include Empatica, BrainCheck, NeuroFlow, Acorai, MayaMD.AI, Omron, WellSense, Eko, VitalConnect, Healios and 82 more.

  • What products does Biofourmis offer?

    Biofourmis's products include Biovitals RPM and 3 more.

Compare Biofourmis to Competitors

VitalConnect Logo

VitalConnect is specializes in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect’s advanced yet easy-to-use platform aims to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers. The company was formerly known as Vigilo Networks. It was founded in 2011 and is based in San Jose, California.

AliveCor Logo

AliveCor focuses on the creation of FDA-cleared machine learning techniques to enable proactive heart care. The FDA-cleared KardiaMobile is a clinically validated mobile EKG solution used by people for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG. The firm serves clients operating in the healthcare sector. It was formerly known as AliveUSA. It was founded in 2011 and is based in Mountain View, California.

TytoCare Logo

TytoCare connects people to clinicians to provide virtual home examinations and diagnosis solutions. TytoCare's solutions are designed to enable a comprehensive medical exam with clinicians, from any location.

Withings Logo

Withings creates smart products and apps to help people across the world take care of their health and well-being. By extending the capabilities of an object through network resources, Withings provides access to computing and storage facility at no extra cost, turning objects into smart connected devices.

Eko Logo

Eko creates digital health solutions. Its solutions include AI-enabled stethoscopes, patient and provider software, and AI-powered analytics that enable doctors, nurses, researchers, and entire health systems to change care for the heart. It serves clients in the healthcare sector. The firm was formerly known as Eko Health. It was founded in 2013 and is based in Oakland, California.

Babyscripts Logo

Babyscripts Virtual Maternity Care is a clinically-validated, obstetrics-specific solution that allows OB/GYNs and other maternal health care providers to deliver a model of prenatal and postpartum care via a mobile app-based platform and remote patient monitoring. The company was founded in 2014 and is based in Washington, DC.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.